WallStSmart

Brookfield Asset Management Ltd. (BAM)vsBlackRock Science and Technology Trust II (BSTZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BAM leads profitability with a 48.9% profit margin vs 0.0%. BSTZ trades at a lower P/E of 6.7x. BAM earns a higher WallStSmart Score of 77/100 (B+).

BAM

Strong Buy

77

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 5.7Quality: 4.0
Piotroski: 2/9Altman Z: 1.97

BSTZ

Avoid

33

out of 100

Grade: F

Growth: 4.3Profit: 5.5Value: 6.7Quality: 6.3
Piotroski: 2/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAM5 strengths · Avg: 9.4/10
Profit MarginProfitability
48.9%10/10

Keeps 49 of every $100 in revenue as profit

Operating MarginProfitability
68.7%10/10

Strong operational efficiency at 68.7%

Revenue GrowthGrowth
60.8%10/10

Revenue surging 60.8% year-over-year

Market CapQuality
$75.49B9/10

Large-cap with strong market position

EPS GrowthGrowth
47.4%8/10

Earnings expanding 47.4% YoY

BSTZ3 strengths · Avg: 10.0/10
P/E RatioValuation
6.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
34.2%10/10

Every $100 of equity generates 34 in profit

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

BAM4 concerns · Avg: 3.8/10
P/E RatioValuation
27.2x4/10

Moderate valuation

Price/BookValuation
10.1x4/10

Trading at 10.1x book value

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

BSTZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BAM

The strongest argument for BAM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 48.9% and operating margin at 68.7%. Revenue growth of 60.8% demonstrates continued momentum.

Bull Case : BSTZ

The strongest argument for BSTZ centers on P/E Ratio, Return on Equity, Debt/Equity.

Bear Case : BAM

The primary concerns for BAM are P/E Ratio, Price/Book, Altman Z-Score. Debt-to-equity of 5.69 is elevated, increasing financial risk.

Bear Case : BSTZ

The primary concerns for BSTZ are Revenue Growth, EPS Growth, Profit Margin.

Key Dynamics to Monitor

BAM profiles as a growth stock while BSTZ is a value play — different risk/reward profiles.

BAM is growing revenue faster at 60.8% — sustainability is the question.

BAM generates stronger free cash flow (393M), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BAM scores higher overall (77/100 vs 33/100), backed by strong 48.9% margins and 60.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Asset Management Ltd.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets.

Visit Website →

BlackRock Science and Technology Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Science and Technology Trust II (BSTZ) is a closed-end fund adeptly managed by BlackRock, focusing on high-growth investment opportunities in the science and technology sectors. The fund targets innovative, forward-thinking companies that are leaders in technological advancements and scientific research, with the objective of maximizing total returns through a well-rounded strategy that emphasizes both capital appreciation and income generation. Leveraging BlackRock's extensive industry expertise, BSTZ provides institutional investors with a unique opportunity for portfolio diversification while aligning with enduring trends in technology and healthcare innovation, positioning them for substantial future growth.

Want to dig deeper into these stocks?